SJ Eliot: PHASE 1 EVALUATION OF LY2606368, A MOLECULARLY-TARGETED CHK1/2 INHIBITOR THERAPY, IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT GROUP 3/GROUP 4 OR SHH MEDULLOBLASTOMA BRAIN TUMORS

SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease. Additionally, a small expansion cohort will be incorporated into the trial at the combination MTD/RP2D (maximum tolerated dose/recommended phase two dose) to detect a preliminary efficacy signal.